ctDNA test in advanced bladder cancer
Treatments studied
Part of Cancer clinical trials.
This trial studies how a blood test that looks for tumor DNA (ctDNA) can help guide treatment in people with advanced bladder cancer that cannot be removed by surgery or has spread. It aims to see if the test results can help doctors choose the best therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced bladder cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your tumor must be measurable on scans (like CT or MRI).
- You must be healthy enough to receive chemotherapy with cisplatin or carboplatin.
- You must have a tumor tissue sample available from a previous biopsy or surgery.
- You should be able to perform daily activities with little to no help (ECOG score 0, 1, or 2).
- Your blood counts and organ function (kidney, liver) must be within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
This trial tests how well platinum-based chemotherapy works in people with advanced bladder cancer that has certain DNA repair gene changes. It aims to see if these genetic markers can predict who benefits most from treatment.
This trial checks if a DNA blood test can help decide who needs extra chemo after bladder or upper urinary tract cancer surgery. It tests whether watching for cancer DNA in the blood can match patients to the right treatment.
This trial uses a blood test to look for small pieces of tumor DNA (ctDNA) after treatment for muscle-invasive bladder cancer. It aims to find out if the test can detect leftover or returning cancer earlier, helping guide next steps.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.